(Q30769719)

English

Remission in patients with active rheumatoid arthritis by tocilizumab treatment in routine clinical practice: results from 3 years of prospectively registered data

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

Remission in patients with active rheumatoid arthritis by tocilizumab treatment in routine clinical practice: results from 3 years of prospectively registered data (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

rheumatoid arthritis

0 references

1 reference

based on heuristic

inferred from title

15

object named as

Eisuke Shono

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

Takashi Shimauchi

17

object named as

Takashi Shimauchi

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

Shigeru Yoshizawa

20

object named as

Shigeru Yoshizawa

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

Yukihide Iwamoto

22

object named as

Yukihide Iwamoto

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

author name string

Yasuharu Nakashima

1

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

Masakazu Kondo

2

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

Takaaki Fukuda

3

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

Hiroshi Harada

4

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

Takahiko Horiuchi

5

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

Takashi Ishinishi

6

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

Hiroshi Jojima

7

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

Koji Kuroda

8

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

Hisaaki Miyahara

9

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

Masayuki Maekawa

10

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

Hiroaki Nishizaka

11

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

Ryuji Nagamine

12

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

Hitoshi Nakashima

13

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

Takeshi Otsuka

14

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

Eiichi Suematsu

16

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

Tomomi Tsuru

18

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

Ken Wada

19

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

Seiji Yoshizawa

21

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

publication date

1 March 2014

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

Modern Rheumatology

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

24

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

258-264

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA.

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2013.854069

21 January 2018

Treating rheumatoid arthritis to target: recommendations of an international task force

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2013.854069

21 January 2018

Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2013.854069

21 January 2018

Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA).

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2013.854069

21 January 2018

Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study.

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2013.854069

21 January 2018

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2013.854069

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2013.854069

21 January 2018

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2013.854069

21 January 2018

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2013.854069

21 January 2018

Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide D

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2013.854069

21 January 2018

Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients--REACTION 52-week study

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2013.854069

21 January 2018

Performance of the new 2011 ACR/EULAR remission criteria with tocilizumab using the phase IIIb study TAMARA as an example and their comparison with traditional remission criteria

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2013.854069

21 January 2018

Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2013.854069

21 January 2018

Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2013.854069

21 January 2018

American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials

1 reference

https://api.crossref.org/works/10.3109%2F14397595.2013.854069

21 January 2018

Identifiers

10.3109/14397595.2013.854069

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30769719&oldid=1739028440"